Celltrion says ACG 2026 data show higher Week 54 remission with subcutaneous vs IV infliximab in ileum-dominant Crohn’s disease

• Celltrion flagged two new ZYMFENTRA analyses for presentation at the ACG 2026 meeting on Oct. 13-14.
• A post hoc review of Phase 3 LIBERTY trials found similar outcomes when patients restarted on subcutaneous dosing following an IV interruption, regardless of prior antibodies.
• A late-breaking pooled, propensity-matched analysis in ileum-dominant Crohn’s disease showed better remission and endoscopic outcomes with subcutaneous maintenance than IV dosing.
• The readouts support positioning ZYMFENTRA as a maintenance option for adults switching from IV infliximab in Crohn’s disease or ulcerative colitis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Celltrion Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN67221) on October 11, 2026, and is solely responsible for the information contained therein.